Before you start or switch an antidepressant medication, offer your patients PGx testing and the possibility of a >2.5x Chance of Remission vs. Standard of Care.
Camille Schrier, Miss America 2020, struggled for 10 years with depression, anxiety, and medication side effects. Camille is partnering with IDgenetix® to tell her story of how pharmacogenomic (PGx) testing may help better match medications to patients. It’s a breakthrough way to further inform physicians to shift away from trial and error and increase their chances of reducing side effects, medication response, or achieving remission for their patients. Check out Camille’s story to see if PGx testing can help patients like you too.
Read Camille's Story
26
15
ADHD, Anxiety, Arthritis, Bipolar Disorder, Depression, Migraine, Musculoskeletal Pain, Neuropathic Pain, Psychosis, Seizure Disorder
10
127
The IDgenetix® report is designed with two simple classifications that clinicians can use to guide medication choices.
Among the genes analyzed, no genetic variants or metabolic interactions were identified that would suggest a need for increased caution or dose adjustments for medications in this category.
One or more genetic variants or metabolic interactions have been identified that would indicate a need for increased caution, dose adjustment or selection of alternate medication.
At IDgenetix® your data and insights belong to you. Our HIPAA-compliant process gives you confidence in data privacy and best-in-class lab technology – and that’s the confidence you can pass on to your patients. IDgenetix® is a CLIA Certified, CAP Accredited Molecular Pharmacogenomics Clinical Laboratory. IDgenetix® testing is offered in all 50 states.
